DGAP-News: iovera Wins Spark Design Award myoscience

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Nov 20, 2013 at 7:15 AM

DGAP-News: iovera Wins Spark Design Award

myoscience 20.11.2013 13:00 --------------------------------------------------------------------------- REDWOOD CITY, Calif., 2013-11-20 13:00 CET (GLOBE NEWSWIRE) -- Myoscience is pleased to announce that the design for the iovera* system has won top honors in the Spark International design competition. The iovera* system was awarded the highest honor (Spark!) in the category of product design, which is a general category that includes medical devices as well as consumer electronics, cookware, and even sports equipment. Myoscience collaborated with LUNAR to design the iovera* system. 'We're honored to have worked with myoscience to design a beautiful and effective device that will help improve the quality of life for countless people,' says Jeff Salazar at LUNAR. The Spark Awards are given based on two primary criteria: the design innovation and creativity, and the impact it will have on quality of life. The iovera* system is a new take on the safe and reliable use of cold in medicine; by miniaturizing and refining the delivery system to be smaller and more precise, the treatments can be tailored to specific indications. The iovera* system has already improved the quality of life for many who have been treated, immediately reducing pain and enabling people to return to their favorite activities as well as smoothing forehead wrinkles for improved appearance. The iovera? system, developed by myoscience, inc. in California, harnesses the power of cold using Focused Cold Therapy(TM), the advanced technology that powers the device. The iovera* treatment works immediately for both health and beauty applications without leaving any toxins or chemicals behind in the body. iovera* is approved in the European Union and Canada for the treatment of wrinkles, and is used for the treatment of pain in the United States. 'We designed the iovera* system to be sophisticated and intuitive,' says myoscience CEO Clint Carnell. 'It has only one button and fits ergonomically in the physician's hand. Our talented team of engineers and the team of designers at LUNAR who worked hard to ensure we created a product that is not only beautiful to look at, but delivers an elegant result that will immediately ease pain or reduce wrinkles. I am very proud of my team at myoscience who made this concept into a reality.' To see the full list of awards: http://www.sparkawards.com/about/news/ To see the press release from Spark: http://www.prweb.com/releases/2013/11/prweb11336709.htm ABOUT THE SPARK AWARD The Spark mission is to promote better living through better design. The criteria are the same for all Spark competitions: does the design 'Spark,' i.e., innovate, change the game and in some way help humanity or the environment we live in. The Spark founders believe Design is an important, relevant tool to help build a better world. We feel that Design and designers act as catalysts, addressing problems and improving our lives and our Earth. www.sparkawards.com ABOUT MYOSCIENCE Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the technology underlying the iovera* treatment, which is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. iovera* has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com. The myoscience logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13581 (c) 2013 myoscience. All rights reserved. iovera* and Focused Cold Therapy are trademarks of myoscience. MKT-0106A CONTACT: MEDIA RELATIONS Alexandra Mack / mediarelations@myoscience.com 650-474-2600 News Source: NASDAQ OMX 20.11.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: myoscience United States Phone: Fax: E-mail: Internet: ISIN: US9902131674 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nomada Fund Launches: A Game-Changer in New Media

Changing the Investment Game In a world where tech isn't the only kingmaker, distribution is the new play. Welcome the Nomada Fund, a fresh face on the investment scene that's swapping cash for exposure. Forget the traditional media-for-equity model that only old-timers still drool over—these guys are taking it up a notch with their new Distribution for Equity approach,...

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Kansai Medical Ushers in New Era of Cancer Research

Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...

AI-Designed Antivirals: A Brave New World

Pushing the Boundaries with AI in Drug Discovery It seems some smart folks over in South Korea are giving the pharma game a fresh twist, pitting artificial intelligence against viral invaders in a newfangled brawl. Professors from Korea University have managed to blend AI's computing prowess with good ol' lab doggedness to sniff out potential antiviral compounds. The...

Revolutionizing Talent Matching with Match2's Latest Upgrades In the churn of today's recruiting jungle, candidates and employers have been grappling with disjointed systems and outdated approaches. Well, Match2 is cutting through that noise with some hefty upgrades. It's got some new toys in the shed—specifically, a beefed-up Universal Candidate Profile™ and an...

TomoIQ Unveils Money Finder at Money20/20 Event

Breaking Down Financial Barriers with AI In the hustle of Money20/20 USA in Las Vegas, TomoIQ dropped a financial bombshell with their latest tool, Money Finder. This isn't just another app in the sea of fintech solutions. Nope, this one promises to cut through the complexities that most folks face when trying to get their financial house in order. An AI Buddy for...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Richard Huffman Joins IFA Board, Strengthens Franchise Ties

Ever wonder how the cogs in this massive machine called franchising keep turning? It's folks like Richard Huffman who step up to the plate, and his recent election to the International Franchise Association (IFA) Board of Directors is worth a second glance. Huffman: A Franchise Veteran Now, Huffman isn't some rookie in the world of franchising. You see, back in '94, he...

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...